Scartozzi, Mario
 Distribuzione geografica
Continente #
NA - Nord America 1.729
AS - Asia 1.067
EU - Europa 547
SA - Sud America 283
AF - Africa 93
Totale 3.719
Nazione #
US - Stati Uniti d'America 1.669
SG - Singapore 366
CN - Cina 269
BR - Brasile 222
HK - Hong Kong 156
VN - Vietnam 142
IT - Italia 140
SE - Svezia 89
DE - Germania 63
GB - Regno Unito 58
CI - Costa d'Avorio 40
FR - Francia 40
CA - Canada 35
AR - Argentina 30
AT - Austria 29
RU - Federazione Russa 29
TR - Turchia 25
BG - Bulgaria 21
IN - India 20
NL - Olanda 19
BD - Bangladesh 18
FI - Finlandia 17
SN - Senegal 15
JP - Giappone 14
IQ - Iraq 13
ZA - Sudafrica 10
ES - Italia 9
MX - Messico 8
VE - Venezuela 8
EC - Ecuador 7
ID - Indonesia 7
UA - Ucraina 7
EG - Egitto 6
NG - Nigeria 6
PK - Pakistan 6
UZ - Uzbekistan 5
CL - Cile 4
CZ - Repubblica Ceca 4
KE - Kenya 4
LT - Lituania 4
PA - Panama 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CO - Colombia 3
CR - Costa Rica 3
MY - Malesia 3
PE - Perù 3
PH - Filippine 3
RO - Romania 3
SA - Arabia Saudita 3
UY - Uruguay 3
AO - Angola 2
BE - Belgio 2
BS - Bahamas 2
ET - Etiopia 2
IE - Irlanda 2
KZ - Kazakistan 2
MA - Marocco 2
NI - Nicaragua 2
NP - Nepal 2
PL - Polonia 2
PY - Paraguay 2
SI - Slovenia 2
SV - El Salvador 2
TN - Tunisia 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CG - Congo 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GD - Grenada 1
GH - Ghana 1
GT - Guatemala 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
LB - Libano 1
LY - Libia 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TM - Turkmenistan 1
Totale 3.719
Città #
Ashburn 223
Singapore 212
Hong Kong 152
Santa Clara 150
San Jose 130
Chandler 102
Fairfield 81
Shanghai 80
Woodbridge 64
Dallas 58
Council Bluffs 48
New York 44
Abidjan 40
Houston 39
Wilmington 35
Boardman 34
Ho Chi Minh City 34
Los Angeles 34
Beijing 32
Seattle 32
Cambridge 31
Hanoi 29
Florence 28
Munich 24
Princeton 24
Vienna 24
Colorado Springs 23
Lawrence 21
Milan 21
Sofia 21
Lauterbourg 19
Istanbul 18
London 17
Medford 16
Dakar 15
Bremen 14
Ann Arbor 13
Buffalo 13
Ottawa 13
São Paulo 13
Frankfurt am Main 12
Tokyo 12
Haiphong 10
Montreal 10
Kent 9
Nuremberg 9
Redondo Beach 9
San Diego 9
Des Moines 8
Turku 8
Baltimore 7
Dearborn 7
Poplar 7
Baghdad 6
Chicago 6
Dong Ket 6
Fuzhou 6
Helsinki 6
Mexico City 6
Miami 6
Orem 6
Rio de Janeiro 6
Serra 6
Amsterdam 5
Bexley 5
Chennai 5
Guangzhou 5
Johannesburg 5
Lagos 5
Nanjing 5
Phoenix 5
Redwood City 5
Boston 4
Curitiba 4
Da Nang 4
Joinville 4
Lancaster 4
Murcia 4
New Delhi 4
Ogden 4
Panama City 4
Porto Alegre 4
Quanzhou 4
Quito 4
San Francisco 4
Seacroft 4
Stockholm 4
Thái Nguyên 4
Bitonto 3
Brasília 3
Brooklyn 3
Bảo Lộc 3
Bắc Ninh 3
Caracas 3
Charlotte 3
City of London 3
Denver 3
Elk Grove Village 3
Formosa 3
Fortaleza 3
Totale 2.343
Nome #
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 181
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 180
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 153
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 137
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 134
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 134
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 132
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 132
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 129
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 125
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 120
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 120
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 119
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 118
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 118
Cholangiocarcinoma: new perspectives for new horizons 117
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 113
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 112
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 111
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 110
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 109
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 109
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 107
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 107
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 105
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 94
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 67
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 61
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 54
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 47
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 44
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 43
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 42
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 39
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 37
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 34
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 33
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 33
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 32
Totale 3.792
Categoria #
all - tutte 12.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.755


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022186 3 8 4 1 11 50 3 11 5 21 21 48
2022/2023396 38 60 32 24 40 45 6 24 88 2 31 6
2023/2024173 14 15 23 4 20 24 15 14 7 1 14 22
2024/20251.033 2 73 33 51 108 172 53 48 95 116 102 180
2025/20261.600 108 186 135 191 148 126 240 121 95 156 62 32
2026/202715 15 0 0 0 0 0 0 0 0 0 0 0
Totale 3.792